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The unique short region of varicella zoster virus (VZV) encodes four genes. One of these, ORF65, is predicted to encode an
11-kDa protein. Antibody to ORF65 protein immunoprecipitated a 16-kDa protein from the membrane fraction of VZV-infected cells.
ORF65 protein was shown to be phosphorylated by casein kinase II. The VZV ORF47 or ORF66 protein kinases were not required
for phosphorylation of ORF65. VZV with a large deletion in ORF65 was constructed and was shown to be dispensable for
replication of virus in cell culture. The herpes simplex virus homolog of VZV ORF65 has been reported to be located in the nucleus
of infected cells and in virions as a tegument protein, whereas the pseudorabies virus homolog is located in the Golgi apparatus
of infected cells and in virions as a type II membrane protein. The ORF65 protein localized to the Golgi apparatus in virus-infected
cells and was located in virions, most likely as a type II membrane protein. Thus, VZV ORF65 more closely resembles its
pseudorabies virus homolog in its localization in infected cells and virions.
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lINTRODUCTION
The varicella-zoster virus (VZV) genome contains two
unique and two large repeat regions. The unique short
region is the shortest of the human herpesviruses and
contains only four open reading frames (ORFs). Two of
these ORFs, ORF66, which encodes a protein kinase,
and ORF67, which encodes glycoprotein I (gI), are not
required for replication of the virus in most cell culture
lines (Cohen and Nguyen, 1997; Heineman et al., 1995;
Mallory et al., 1997). In contrast, the product of ORF68,
which encodes gE, appears to be essential for virus
replication in cell culture (Mallory et al., 1997; Cohen et
l., unpublished data). The fourth gene in the unique
hort region is ORF65. The product of ORF65 is predicted
o encode an 11-kDa protein with a hydrophobic car-
oxyl-terminus (Davison and Scott, 1986). The amino half
f VZV ORF65 has 20% serine and threonine residues
nd thus might be phosphorylated.
VZV ORF65 is the homolog of the herpes simplex virus
HSV) US9 protein. Most of the alphaherpesviruses in-
luding HSV-1 (Frame et al., 1986), HSV-2 (Dolan et al.,
998), equine herpesvirus 1 (EHV-1) (Telford et al., 1992),
HV-4 (Telford et al., 1994), bovine herpesvirus 1 (Leung-
ack et al., 1994), and pseudorabies virus (PRV) (Brideau
t al., 1998) encode US9 homologs. Two alphaherpesvi-
uses, Marek’s disease virus (Brunovskis et al., 1995) and
1 To whom correspondence and reprint requests should be ad-
ressed at National Institutes of Health, NIAID, Medical Virology Sec-V
ion, Laboratory of Clinical Investigation, Bldg. 10, Room 11N214, Be-
hesda, MD 20892. Fax: (301) 496-7383. E-mail: jcohen@niaid.nih.gov.
0042-6822/01
62erpesvirus of turkeys (Zelnick et al., 1993), do not con-
ain US9 homologs.
Each of the herpesvirus US9 proteins contains casein
inase II and tyrosine kinase motifs. The HSV-1 and PRV
roteins are present in infected cells as a series of
hosphorylated polypeptides (Brideau et al., 1998; Frame
t al., 1986). Each contains a large number of serine and
hreonine residues in the amino half of the protein, fol-
owed by a region containing basic amino acids and a
ydrophobic terminus.
The HSV-1 US9 protein was previously reported to be
ocated in the tegument of virions (Frame et al., 1986), while
he PRV protein is located in the virion envelope (Brideau et
l., 1998). In addition, although the HSV-1 US9 protein is
ocalized in the nucleus of infected cells (Frame et al., 1986),
he PRV protein is localized to the Golgi of infected cells
Brideau et al., 1998). Since VZV, HSV-1, and PRV are all
embers of the alphaherpesvirus subfamily, we have char-
cterized the VZV ORF65 protein to determine whether it
ore closely resembles its HSV-1 or PRV homolog. Here
e show that VZV ORF65 protein shares a number of
eatures with its PRV counterpart, including its localization
n the Golgi of infected cells and its likely topology in virions
s a type II membrane protein. Furthermore, we show that
RF65 is phosphorylated by casein kinase II.
RESULTS
ZV ORF65 encodes a 16-kDa membrane protein
ocalized to the Golgi apparatus
To determine whether ORF65 protein is expressed in
ZV-infected cells, rabbit antibody was produced to a
63VZV ORF65 IS PHOSPHORYLATED BY CASEIN KINASE IIGST-ORF65 fusion protein. The sequence of ORF65 in
the fusion protein, derived from the Oka strain of VZV,
was identical to that of the Dumas strain of VZV (Davison
et al., 1986). Immunoprecipitation of infected cell lysates
with the antibody detected a 16-kDa protein in VZV-
infected cells; however, ORF65 protein was not detected
in lysates from uninfected cells (Fig. 1A). Immunoprecipi-
tation using monoclonal antibody to VZV glycoprotein E
(gE) was used as a control for infection (Fig. 1B).
To localize ORF65 protein in VZV-infected cells, cyto-
solic and membrane fractions were prepared and immu-
noprecipitated with antibody to ORF65 protein. ORF65
protein was localized in the membranes of VZV-infected
cells, but not in the cytosol (Fig. 2). Immunoprecipitation
with antibody to VZV gE showed that the glycoprotein
was also located in the membrane of virus-infected cells.
To further localize ORF65 protein, uninfected and VZV-
infected cells were costained with rabbit antibody to
ORF65 protein and mouse monoclonal antibody to adap-
tin AP-1, which localizes to the Golgi apparatus. ORF65
localized adjacent to the nucleus and colocalized with
the Golgi apparatus (Fig. 3).
To confirm that ORF65 is localized in the Golgi, VZV-
infected cells were treated with brefeldin A, which re-
sults in dissolution of the Golgi with transport of Golgi
proteins to the endoplasmic reticulum. ORF65 protein
was redistributed from its perinuclear location (Fig. 4A)
to a more diffuse cytoplasmic pattern in brefeldin A-
treated cells (Fig. 4B). Removal of brefeldin A results in
restoration of the Golgi apparatus with reappearance of
proteins in the Golgi. VZV-infected cells that had been
treated with brefeldin A, washed, and incubated with
media again showed ORF65 protein in a perinuclear
FIG. 1. Expression of ORF65 protein in VZV-infected cells. (A) A
16-kDa protein is immunoprecipitated from cells infected with VZV
ROka, but not cells infected with ORF65 deletion mutants. (B) Cells
infected with ROka and ORF65 deletion mutants express proteins of 65
and 100 kDa that react with antibody to VZV gE. Numbers indicate
molecular weight of proteins in kilodaltons.pattern.VZV ORF65 protein is located in virions
Virions were purified from cells infected with an early-
passage clinical isolate of VZV by centrifugation. Super-
natants from the centrifugation and insoluble viral parti-
cles were boiled in SDS–sample buffer, subjected to
SDS–polyacrylamide electrophoresis, and immunoblot-
ted with antibody to ORF65 protein. ORF65 protein was
present in the viral pellet (Fig. 5A). To control for the
purity of the virion preparations, additional aliquots were
immunoblotted with antibodies to VZV gE and ORF61
protein. Although gE is present in the virion, ORF61
protein was previously shown to be absent from these
particles (Kinchington et al., 1996). As expected, glycop-
rotein E was present in virions (Fig. 5B), while ORF61
protein was absent from virions (Fig. 5C).
Localization of VZV ORF65 within the virion
VZV ORF65, like its PRV and HSV homologs, is pre-
dicted to be a type II membrane protein with its amino-
terminus located in the cytosol and a hydrophobic series
of amino acids at its carboxyl-terminus located in the
plasma membrane. The sequence of the protein predicts
a 78 amino acid intracellular domain, followed by an 18
amino acid transmembrane domain, and a 6 amino acid
extracellular domain. Therefore, treatment of purified viri-
ons with protease may result in a subtle change in
molecular mass on polyacrylamide gels.
FIG. 2. VZV ORF65 protein is expressed in the membranes of VZV-
infected cells. Immunoprecipitation using antibody to ORF65 detects a
16-kDa protein in the membrane fraction of virus-infected cells, and
antibody to VZV gE detects a 100-kDa protein in the membrane of the
infected cells. A 55-kDa protein of unknown origin coimmunoprecipi-
tates with ORF65 protein in VZV-infected cells. Numbers indicate mo-
lecular weight of proteins in kilodaltons.
-conjug
64 COHEN ET AL.VZV virions treated with Nonidet P-40 (NP-40), followed
by electrophoresis and blotting with antibody to VZV
ORF65 protein, did not result in loss of the protein or an
apparent change in the molecular mass (Fig. 6A). Treat-
ment with proteinase K did not affect the amount of
protein present, indicating that the vast majority of the
protein is located in the membrane or inside the virion
and is thus protected from degradation. However, the
size of the ORF65 protein in proteinase K-treated virions
appeared to be slightly smaller (Fig. 6A, compare lane 3
with lanes 1 and 2), suggesting that a very small portion
of the protein is located on the outside of the cell and is
susceptible to proteinase degradation. In contrast, treat-
ment with both NP-40 and proteinase K resulted in com-
plete degradation of the protein, indicating that the trans-
FIG. 3. VZV ORF65 protein localizes to the Golgi apparatus. VZV
permeabilized with saponin, and stained with rabbit antibody to ORF65
red-conjugated goat anti-rabbit antibody and fluorescein isothiocyante
green (B), or red and green (C) filters.
FIG. 4. Treatment of VZV-infected cells with brefeldin A results in redi
were left untreated (A), treated with brefeldin A (B), or treated with bref
fixed, treated with saponin, and stained with rabbit antibody to ORF65 prote
shows ORF65 protein in the Golgi.membrane and intracellular portions of the protein are
susceptible to proteolysis following disruption of the en-
velope.
To control for the proteinase and detergent treatment
of virions, we also immunoblotted another aliquot of
virions with antibodies to the VZV ORF10 tegument pro-
tein and to VZV gC, a type I membrane protein. As
expected for a type I membrane protein, gC was resis-
tant to detergent treatment alone, but was degraded in
the presence of proteinase K (Fig. 6B). Nearly complete
degradation of gC with another proteinase, trypsin, was
previously reported (Kinchington et al., 1995). Also as
predicted, the ORF10 tegument protein was resistant to
digestion with proteinase K, but susceptible to digestion
with both NP-40 and proteinase K (Fig. 6B).
d (A–C) or uninfected (D–F) cells were fixed in paraformaldehyde,
n and murine monoclonal antibody to adaptin AP-1, followed by Texas
ated goat anti-mouse antibody. Cells were photographed with red (A),
on of ORF65 protein from the Golgi to the cytoplasm. VZV-infected cells
, washed, and incubated with medium for 1 h (C). The cells were then-infecte
proteistributi
eldin Ain followed by Texas Red-conjugated anti-rabbit antibody. Arrowhead
65VZV ORF65 IS PHOSPHORYLATED BY CASEIN KINASE IITo further determine whether ORF65 protein is in the
envelope or tegument, virions were incubated in the
presence or absence of NP-40 and centrifuged. The
resulting pellets and supernatants were immunoblotted
with antibodies to ORF65 or ORF10 proteins. Envelope
proteins should be released from virions with NP-40,
while tegument proteins should remain in the virion. A
substantial portion of ORF65 protein was released into
the supernatant after NP-40 treatment (Fig. 7A). In con-
trast, the ORF10 tegument protein remained in pelleted
virions after treatment with NP-40 (Fig. 7B). Taken to-
gether, these experiments suggest that VZV ORF65 is a
type II membrane protein in virions.
FIG. 5. VZV ORF65 protein is located in the virion. VZV virions were
isolated from melanoma cells and boiled in SDS–sample buffer. Viral
proteins were separated by electrophoresis, transferred to nylon mem-
branes, and blotted with antibodies to ORF65 protein (A), glycoprotein
E (ORF68) (B), or ORF61 protein (C). In each panel lane 1 is supernatant
obtained from the virion preparation; lane 2 is solubilized virions.
Numbers indicate molecular weight of proteins in kilodaltons.
FIG. 6. VZV ORF65 is likely a type II membrane protein in virions.
Purified VZV virions were treated with Nonidet P-40 (NP-40), proteinase
K, NP-40 and proteinase K, or buffer alone, and then subjected to
polyacrylamide gel electrophoresis, transferred to membranes, and
blotted with antibody to VZV ORF65 protein (A) or VZV gC and ORF10
protein (B). Numbers indicate molecular weight of proteins in kilodal-
tons.VZV ORF65 is phosphorylated in the absence of the
VZV-encoded protein kinases
VZV ORF65 contains serine and tyrosine residues that
could be sites for phosphorylation. VZV-infected cells
were labeled with [33P]orthophosphate, cell lysates were
prepared, and immunoprecipitations were performed us-
ing anti-ORF65 protein antibody. ORF65 was present as a
phosphoprotein in VZV ROka-infected cells (Fig. 8A).
When cells were infected with a VZV mutant, which is
unable to express both the VZV ORF47 and ORF66
serine-threonine protein kinases, ORF65 was still phos-
phorylated.
As a control, additional aliquots of the lysates were
immunoprecipitated with antibody to VZV ORF32 protein.
ORF32 protein was previously shown to undergo post-
translational modification by the ORF47 protein (Reddy et
al., 1998). As expected, the size of the larger ORF32
phosphoprotein was diminished in cells infected with the
VZV mutant unable to express ORF47 and ORF66.
To further verify that ORF65 protein is phosphorylated,
VZV-infected cells were labeled with [35S]methionine,
ORF65 protein was immunoprecipitated, and the cells
were treated with alkaline phosphatase. ORF65 protein
was slightly reduced in size for cells infected with ROka,
ROka66S, or ROka47S after treatment with alkaline phos-
phatase compared to cells incubated with buffer alone
(Fig. 8B). No apparent difference in size was noted in
ORF65 immunoprecipitated from cells infected with VZV
ROka compared to cells infected with ROka47S or
ROka66S that had not been treated with alkaline phos-
phatase. These findings suggest that ORF65 is phos-
phorylated by a protein kinase other than ORF47 or
FIG. 7. VZV ORF65 protein is in the membrane of virions. Virions were
incubated with or without NP-40 and centrifuged. The pellet and su-
pernatant were immunoblotted with antibody to ORF65 (A) or ORF10 (B)
proteins.ORF66 protein.
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66 COHEN ET AL.VZV ORF65 protein is phosphorylated by casein
kinase II
VZV ORF65 is predicted to have two casein kinase II
phosphorylation sites, but not a casein kinase I site.
Amino acids 46 to 50 and 52 to 55 contain the putative
casein kinase II phosphorylation sites SDSE and TADE,
respectively.
To determine whether ORF65 is phosphorylated by
casein kinases, ORF65 protein was immunoprecipitated
from VZV-infected cells, heated at 60°C to inactivate
contaminating protein kinases, and incubated with ca-
sein kinases I or II and [g-32P]ATP. A 16-kDa phospho-
protein, corresponding to ORF65 protein, was present in
VZV-infected cells incubated with casein kinase II (Fig.
9A). This protein was absent in uninfected cells. ORF65
protein was not detected in immunoprecipitates from
VZV-infected cells that had been treated with casein
kinase I.
Two controls were performed for casein kinase activ-
ity. First, ORF65 protein that had been immunoprecipi-
tated from infected cells and heated to 60°C was incu-
bated with [g-32P]ATP in the absence of casein kinase I
or II. No phosphoprotein was detected. Second, VZV gE,
which is known to be phosphorylated by both casein
kinase I and casein kinase II (Grose et al., 1989), was
immunoprecipitated from VZV-infected cells and incu-
bated with casein kinases I or II and [g-32P]ATP. Phos-
hoproteins of 90 to 100 kDa were detected, correspond-
FIG. 8. VZV ORF65 encodes a phosphoprotein. (A) Uninfected or
VZV-infected cells were radiolabeled with [33P]orthophosphate and
ysates were immunoprecipitated with antibody to ORF65 protein (lanes
–3) or ORF32 protein (lanes 4–6). (B) Uninfected or VZV-infected cells
ere radiolabeled with [35S]methionine, lysates were immunoprecipi-
ated with antibody to ORF65 protein, and in some cases were treated
ith alkaline phosphatase. Comparison of the phosphatase-minus
anes of ROka, ROka66S, and ROka47S show ORF65 proteins of the
ame size, while the phosphatase-plus lanes show proteins of slightly
maller size. Numbers indicate molecular weight of proteins in kilodal-
ons.ng to gE, in cells incubated with either kinase (Fig. 9B).
c
rZV ORF65 is dispensable for replication of VZV in
ell culture
To determine whether ORF65 is necessary for growth
f VZV in cell culture, a VZV ORF65 deletion mutant was
onstructed. Two independent cosmids, MstII A-65DA
nd MstII A-65DB, were constructed that have deletions
n ORF65 (Fig. 10). Melanoma cells were transfected with
osmids NotI A, NotI BD, MstII B, and MstII A-65DA or
stII A-65DB, and plasmid pCMV62. Cytopathic effects,
FIG. 9. VZV ORF65 is phosphorylated by casein kinase II. Lysates
from uninfected (lanes 1, 3, 5) or VZV-infected (lanes 2, 4, 6) cells were
immunoprecipitated with antibody to ORF65 (A) or VZV gE (B), heated to
60°C, and incubated with [g-32P]ATP and casein kinase I (CK1), no
kinase, or casein kinase II (CK2). The immunoprecipitates were
washed and fractionated on polyacrylamide gels. The arrow in (A)
indicates ORF65 protein in the lysate treated with casein kinase II.
Nonspecific bands of similar size are seen in the samples treated with
casein kinase I that migrate slightly faster than ORF65 protein.
FIG. 10. Construction of recombinant VZV with a deletion in ORF65.
The VZV genome is 124,884 bp in length (line 1) and contains unique
long (UL), unique short (US), terminal repeat (TR), and internal repeat (IR)
NA segments (line 2). NotI and MstII DNA restriction fragments used
o construct parental VZV are shown (lines 3 and 4). Cosmid MstII
-65D (line 5) has a deletion beginning 111 bp upstream of the ORF65
tart codon and ending at amino acid 24 of ORF65. Numbers for cosmid
stII A-65D indicate the site of the deletion. Two identical, independentosmids, MstIIA-65DA and MstIIA-65DB, were used to construct vi-
uses with a deletion in ORF65.
67VZV ORF65 IS PHOSPHORYLATED BY CASEIN KINASE IItypical for those seen with parental VZV, were present in
the cells after transfection. Two clones of the resulting
viruses, ROka65DA and ROka65DB, were propagated for
further analysis.
Virion DNA was prepared from cells infected with VZV
ROka, ROka65DA, and ROka65DB, and Southern blots
were performed to verify that the genomes had the ex-
pected configuration. Digestion of virion DNA from VZV
ROka with BamHI and hybridization with a probe con-
taining ORF65 and adjacent sequences resulted in a
2.1-kb band, while digestion of DNA from ROka65DA or
ROka65DB resulted in a 1.9-kb band, resulting from the
deletion in ORF65 (Fig. 11). Similarly, digestion of ROka
DNA with NcoI resulted in bands of 2.7 and 1.2 kb, while
digestion of ROka65DA or ROka65DB DNA yielded a
band of 3.7 kb resulting from the loss of an NcoI site with
the deletion in ORF65. Digestion of virion DNAs from
ROka or the OR65 deletion mutants with EcoRI or BamHI
followed by hybridization with a probe containing all four
VZV cosmids gave identical patterns of restriction frag-
FIG. 11. Southern blots of virion DNA from cells infected with parental
(ROka) or ORF65 deletion mutants. (A) Digestion of ROka DNA with
BamHI shows a fragment of 2.1; digestion of ROka65DA or ROka65DB
shows a fragment of 1.9 kb, resulting from the deletion in ORF65. (B)
Digestion of ROka DNA with NcoI shows fragments of 2.7 and 1.3 kb;
digestion of ROka65DA or ROka65DB shows a fragment of 3.7 kb,
resulting from the deletion in ORF65. Numbers indicate molecular
weights in kilobase pairs.ments (data not shown).To verify that cells infected with the ORF65 deletion
mutants could not express the VZV protein, melanoma
cells were infected with ROka65DA and ROka65DB and
lysates were immunoprecipitated with anti-ORF65 anti-
body. Whereas cells infected with ROka expressed a
16-kDa protein, cells infected with the ORF65 deletion
mutants did not express this protein (Fig. 1A). As a
control, the cells infected with the deletion mutants did
express VZV gE (Fig. 1B).
VZV unable to express ORF65 protein is not impaired
for replication in cell culture
Infection of human melanoma, fibroblast, schwan-
noma, neuroblastoma, and osteosarcoma cells, and Vero
cells with the ORF65 deletion mutants resulted in
plaques of similar morphology and size when compared
to that resulting from infection of the cells with the pa-
rental ROka virus (Cohen et al., unpublished data). To
verify this result in melanoma cells, cells were infected
with VZV ROka, ROka65DA, and ROka65DB and aliquots
of infected cells were titered at various times after infec-
tion. VZV ROka65DA and ROka65DB grew to titers similar
to those seen in cells infected with VZV ROka (Fig. 12).
DISCUSSION
We have shown that VZV ORF65 encodes a 16-kDa
protein in infected cells. In contrast to the single phos-
phoprotein we detected on SDS–polyacrylamide gel
electrophoresis for ORF65, the homolog of the protein in
HSV-1 and PRV is present in multiple forms. Antibody to
the HSV protein immunoprecipitated 12 different phos-
phorylated forms of the protein ranging from 12 to 20 kDa
(Frame et al., 1986), whereas the PRV homolog was
present in at least three different phosphoforms from 17
to 20 kDa (Brideau et al., 1998). These results suggest
FIG. 12. Growth of parental and ORF65 deletion mutants in mela-
noma cells. Cells were infected with virus and at various times after
infection, the cells were treated with trypsin, and the virus titer was
determined.
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68 COHEN ET AL.that the posttranslation modification of each of the her-
pesvirus ORF65 homologs is different. More recent ex-
periments indicated that the HSV-1 homolog of VZV
ORF65 is ubiquitinated and associates with proteo-
somes (Brandimarti and Roizman, 1997). Interestingly,
while ubiquitin is usually conjugated to lysine residues,
the HSV-1 ORF65 homolog lacks any lysines. VZV ORF65
does contain lysines; however, we were unable to dem-
onstrate that the protein is ubiquitinated (Cohen et al.,
unpublished data).
VZV ORF65 is protein phosphorylated by casein
kinase II, but not by casein kinase I. Whereas the HSV
and PRV homologs contain a casein kinase II motif,
these other viral proteins have not been reported to be
phosphorylated by the cellular kinase. Although we
found that the VZV ORF47 or ORF66 protein kinases
are not required for phosphorylation of ORF65 protein,
the homolog of ORF65 in HSV, US9, was previously
reported to be the target of the HSV-2 US3 protein
kinase (Daikoku et al., 1994).
We found that VZV ORF65 is located in the Golgi
apparatus of infected cells and is present in virions,
most likely as a type II membrane protein. While
Frame et al., (1996) reported that the HSV-1 homolog of
ORF65 is located in the tegument of virions and lo-
cated in the nucleus of infected cells, Brideau and
colleagues (1998) showed that PRV US9, the PRV ho-
molog of ORF65 protein, is a type II membrane protein
present in the virion envelope. Furthermore, they
showed that the PRV protein localizes near the Golgi
apparatus and shuttles from the plasma membrane to
the Golgi (Brideau et al., 1999). VZV shares the
ileucine and acidic domain endocytosis motifs
resent in its PRV counterpart. Thus, VZV ORF65 more
losely resembles its PRV homolog than its HSV ho-
olog, and might undergo shuttling from the surface of
he cell to the Golgi, like its PRV counterpart.
The VZV ORF65 protein is dispensable for replication
n cell culture like its US9 homologs in HSV-1 (Long-
ecker et al., 1986), PRV (Mettenleiter, 1988), and EHV-1
(Flowers and O’Callaghan, 1992). HSV-1 lacking US9 is
unimpaired for neurovirulence or latency in mice (Nishi-
yama et al., 1993). However, PRV US9 null mutants are
impaired for anterograde spread in the visual and corti-
cal pathways in rats and have reduced neurovirulence
when the viruses are inoculated into the eye (Brideau et
al., 2000a). In fact, the two tyrosine (Y49, Y50) and serine
(S51, S53) residues in PRV US9 that are essential for
spread of PRV US9 mutants in the nervous system
(Brideau et al., 2000b) are conserved in VZV ORF65 (Y44,
Y45, S46, S48). Thus, it will be of interest to determine
whether VZV unable to express ORF65 more closely
resembles the HSV-1 or PRV US9 mutant when tested for
virulence in animals. fMATERIALS AND METHODS
Cells and viruses
Human melanoma (MeWo) cells (from Charles Grose)
were used for transfection and propagation of viruses.
Human fibroblast (MRC-5), osteosarcoma (U2OS), and
neuroblastoma (SK-N-SH) cells were obtained from the
American Type Culture Collection (Manassas, VA), and
schwannoma cells (ST88-14) were obtained from Cynthia
Morton. Recombinant viruses were obtained from cos-
mids derived from the VZV Oka vaccine strain. Recom-
binant Oka VZV (ROka), virus with stop codons in ORF47
(ROka47S), ORF66S (ROka66S), in both ORF47 and
ORF66 (ROka47S/66S), and with a deletion in ORF32
(ROka32D) were described previously (Heineman et al.,
1995, 1996; Reddy et al., 1998). An early-passage clinical
isolate (VZV strain Molly) was used for preparation of
virions.
Plasmids and cosmids
VZV cosmids NotI A, NotI BD, MstII A, and MstII B
ncompass the entire VZV genome (Fig. 10). To produce
ZV with a deletion in ORF65, VZV cosmid MstII A was
artially digested with HhaI using the recA-assisted re-
triction endonuclease cleavage procedure (Ferrin and
amerini-Otero, 1991). Two single-stranded 60-base oli-
onucleotides (ATG GCT GTT ATC GTT GTA TTA TTT
GT TGC GCT CGC GGG GTT ACC ACC GCT TCC ATC
GT and TAG ATT ATT CAT CAA TAG GTC GTT TAA AGC
CG TTT TCA TAA ACG TTG TCA GCT ATA CCG) cen-
ered around the HhaI sites at VZV nucleotides 112,570
nd 112,754 (Davison and Scott, 1986) were annealed to
osmid VZV MstII A using E. coli recA protein. HhaI
ethylase and S-adenosylmethionine were added to the
osmid to methylate the additional HhaI sites in the
osmid. The oligonucleotide–recA complexes were dis-
ociated from the cosmid by heating to 65°C and the
NA was then precipitated and digested with HhaI. The
arge DNA fragment, lacking VZV nucleotides 112,570 to
12,754, was ligated to itself and inserted into E. coli.
wo cosmids, VZV MstII A-65DA and VZV MstII A-65DB,
ere selected and the junction of the deletion in ORF65
as sequenced. These cosmids contain a deletion be-
inning 111 bp upstream of the ORF65 start codon and
nding at amino acid 24 of ORF65.
outhern blots
VZV DNA was purified from nucleocapsids; cut with
coRI, BamHI, or NcoI; fractionated on agarose gels; and
ransferred to nylon membranes. The membranes were
ybridized to [32P]dCTP-radiolabeled probes correspond-
ng to all four VZV cosmid DNAs or to the BamHI Q
ragment (VZV nucleotides 111,888 to 114,042).
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69VZV ORF65 IS PHOSPHORYLATED BY CASEIN KINASE IITransfections and growth characteristics of
recombinant VZV
To produce VZV with a deletion in ORF65, melanoma
cells were transfected with 1 mg of cosmid NotI A, NotI
BD, MstII B, and MstII A-65DA or MstII A-65DB; 50 ng of
lasmid pCMV62; and 2 mg of sheared salmon sperm
DNA using the calcium phosphate procedure.
Growth curves for recombinant VZV were performed
by infecting melanoma cells with cells containing about
200 plaque-forming units (PFU) of VZV. At 1, 2, 3, 4, and 5
days after infection, the cells were treated with trypsin,
and serial dilutions were used to inoculate uninfected
melanoma cells. Plaques were fixed and stained with
crystal violet 7 days after infection.
Generation of antibody to ORF65 protein
The coding region of ORF65, from codons 5 to 102,
was amplified from cosmid DNA using PCR. Primer CGG
GGA TCC AAC ACC ATG GAG GGT GAG GCC contains a
BamHI site followed by VZV nucleotides 112,608 to
112,628. Primer GCG GAA TTC TTA TCC AAC AAA TTG
TGA CG contains a BamHI site and VZV nucleotides
112,331 to 112,351. The amplified DNA was digested with
BamHI and cloned into plasmid pGEX-2T. E. coli contain-
ing the plasmid were lysed and the GST-ORF65 fusion
protein was bound to glutathione–Sepharose, washed
extensively, and eluted with reduced glutathione.
Rabbits were immunized with 150 mg of GST-ORF65
fusion protein in complete Freund’s adjuvant followed by
two additional immunizations with the fusion protein in
incomplete Freund’s adjuvant. Rabbit antiserum contain-
ing ORF65 antibody was absorbed three times with un-
infected melanoma cells prior to use.
Immunoprecipitations and immunoblots
VZV-infected and uninfected cells were radiolabeled
with [35S]methionine or [33P]orthophosphate and lysed.
The supernatant was then incubated with rabbit anti-
ORF65 antibody, murine anti-gE monoclonal antibody
(Chemicon, Temecula, CA), or rabbit anti-ORF32 antibody
(Reddy et al., 1998) followed by protein A–Sepharose.
Immune complexes were washed extensively and frac-
tionated on SDS–polyacrylamide gels. Immune com-
plexes were also treated with 10 U of calf alkaline phos-
phatase for 30 min at 37°C, additional phosphatase was
added, the incubation was repeated, and the immune
complexes were then fractionated on gels.
Membrane and cytosolic fractions from uninfected or
VZV-infected melanoma cells were prepared as de-
scribed previously (Cohen and Seidel, 1995).
Phosphorylation assays
VZV proteins were immunoprecipitated from VZV-in-
fected cells using polyclonal antibody to ORF65 proteinor monoclonal antibody to gE, followed by protein
A–Sepharose. The immune complexes were washed five
times, washed in casein kinase I or II buffer twice,
resuspended in casein kinase buffer, and heated to 60°C
for 10 min. Casein kinase I (1000 U) or casein kinase II
(500 U) (New England Biolabs, Beverly, MA) was added
with 20 mCi of [g-32P]ATP and the immune complexes
ere incubated for 30 min at 30°C. The immune com-
lexes were washed five times, boiled in SDS–sample
uffer, and fractionated on polyacrylamide gels.
mmunofluorescence
Uninfected and VZV-infected cells were grown on
lass coverslips, washed in PBS, incubated with 2%
araformaldehyde for 10 min, washed, and incubated
ith 0.3% saponin and 1% bovine serum albumin in PBS
or 20 min. The cells were then washed, incubated with
0% normal goat serum to block nonspecific antibody
inding, and incubated with rabbit anti-ORF65 antibody
nd murine monoclonal antibody to adaptin protein AP-1
which localizes to the Golgi apparatus) (Sigma, St.
ouis, MO) for 1 h, washed, and incubated with a mixture
f Texas red-conjugated goat anti-rabbit antibody and
luorescein isothiocyanate-conjugated goat anti-mouse
ntibody. After washing, the cells were examined by
mmunofluorescence microscopy.
In some experiments VZV-infected cells were treated
ith brefeldin A (Epicentre Technologies, Madison, WI)
t 1 mg/ml for 30 min. The cells were then fixed in
araformaldehyde, incubated with saponin, and stained
ith anti-ORF65 antibody as described above. Alterna-
ively, virus-infected cells were treated with brefeldin A
or 30 min, washed, incubated with medium for 1 h, fixed,
reated with saponin, and stained with antibody to ORF65
rotein.
reparation of virions
Virus particles were purified from VZV-infected MeWo
ells as previously described (Kinchington et al., 1995)
ith the following modifications. Cells were infected with
n early-passage clinical isolate of VZV (strain Molly),
nd cells showing 80% cytopathic effects were scraped,
elleted at low speed, and homogenized using a Dounce
pparatus. The cell culture media was also pelleted at
0,000 g for 2 h at 4°C to obtain virus particles in the
ulture media. The material from the Dounce homogeni-
ation and the pelleted culture media were pooled, son-
cated, and clarified by low-speed centrifugation. The
upernatant was centrifuged on a 5–15% Ficoll 400 gra-
ient for 2 h at 25,000 g at 4°C and the band containing
irus particles was collected and centrifuged on a sec-
nd 5–15% Ficoll gradient. Viral particles were diluted in
BS, pelleted by centrifugation at 40,000 g for 2 h at 4°C,
nd resuspended in PBS containing 100 mM each of theprotease inhibitors TLCK and TPCK. The supernatant
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70 COHEN ET AL.from this latter centrifugation, and the virus pellet were
each boiled in SDS–sample buffer, fractionated on poly-
acrylamide gels, transferred to nylon membranes, and
immunoblotted using antibody to ORF65 protein, gE, or
ORF61 protein (Kinchington et al., 1995; Ng et al., 1995).
ocalization of ORF65 protein in virions
Proteinase K protection assays were performed as
escribed previously (Brideau et al., 1998). Virions were
elleted to remove protease inhibitors and were treated
or 1 h at room temperature with 1% NP-40, proteinase K
10 mg/ml), NP-40 and proteinase K, or buffer alone. The
reaction was terminated by the addition of PMSF to a
final concentration of 2 mM and boiling in sample buffer
containing 2% SDS. The proteins were fractionated on
polyacrylamide gels, transferred to nylon membranes,
and immunoblotted with rabbit antibody to ORF65 pro-
tein, glycoprotein C (a kind gift from P. Kinchington), or
ORF10 protein (Moriuchi et al., 1995). The blots were then
ncubated with horseradish peroxidase-conjugated anti-
ouse antibody and developed using enhanced chemi-
uminescence.
Localization of protein in virions was performed as
reviously described (Kinchington et al., 1992). Virions
ere incubated in PBS with or without 1% NP-40 at room
emperature for 30 min. The samples were then centri-
uged at 100,000 g at 4°C for 30 min. The resulting pellets
nd supernatants were boiled in sample buffer contain-
ng 2% SDS, fractionated on polyacrylamide gels, trans-
erred to nylon membranes, and immunoblotted with
abbit antibody to ORF65 protein or ORF10 protein fol-
owed by horseradish peroxidase-conjugated anti-rabbit
ntibody.
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